Carl Zeiss Meditec (ETR:AFX) reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management pointed to currency headwinds, soft equipment demand and pressure in China’s…
traocular lens business. Chief Executive Andreas Pecher said the company’s top line and earnings in the second quarter “still remained weak,” mainly due to foreign exchange effects and an unfavorable product mix, including lower intraocular lens sales in China
For the first six months, order entry totaled EUR 1.038 billion, down 5.2% year over year, or 2.3% on a currency-adjusted basis. Revenue fell 5.7% to EUR 991 million, or 2.8% on a constant-currency basis. Adjusted EBITDA declined to EUR 60.5 million, with the adjusted EBITDA margin falling to 6.1% from 10.7% a year earlier.
Reported EBITDA was EUR 39 million, representing a 3.9% margin. Pecher attributed the drop in profitability to negative currency effects, an unfavorable product mix and negative operating leverage, while noting that core operating expenses remained stable. Ophthalmology Weighed Down by China IOL Issues Chief Financial Officer Justus Felix Wehmer said the Ophthalmology strategic business unit posted revenue of EUR 754 million in the first half, down 6.7% year over year, or 4.2% on a currency-adjusted basis.